RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
SPARK has extended its influence to an additional 9.47 million students worldwide
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
Subscribe To Our Newsletter & Stay Updated
